Latest news with #StevenChance
Yahoo
4 days ago
- Business
- Yahoo
Oxford Brain Diagnostics initiates dementia diagnostic commercialisation
Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans. The UK company's cloud-based Cortical Disarray Measurement (CDM) Insights software processes MRI scan data to monitor patient brain changes across multiple stages of life, outputting the data as percentiles of a normative population distribution to provide an "objective, quantifiable measure of neurodegeneration". According to OBD, CDM's assessment of microstructural and macrostructural measurements, as well as cortical thickness, will bring methods of analysis to assist clinicians in the early detection of neurodegeneration currently unavailable on the US market. CDM Insights received a breakthrough device designation from the US Food and Drug Administration (FDA) in 2020 and 510(k) clearance from the agency in January 2025. Intended for use by healthcare practitioners, including neurologists and radiologists, OBD states that the CDM software will be made available to all US healthcare facilities. OBD CEO and co-founder Dr Steven Chance commented: 'Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage. 'These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease.' Spun out from the University of Oxford in 2018, OBD stated that it had reached this stage in its development due to a 2023 funding round led by the London-headquartered Business Growth Fund (BGF). This included additional support from existing investors, including the Oxford Technology & Innovations Fund (OTIF). Dr Chance continued: 'The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health.' The ability to detect neurodegenerative conditions earlier is an area of rising importance in pharmacology. A recent open-label extension (OLE) study (NCT06424236) of Roche's discontinued Alzheimer's drug, gantenerumab, showed signs that it could prevent the onset of the disease. Data from the OLE published in The Lancet demonstrated that the anti-amyloid drug cut the risk of developing symptoms by 50% for a subgroup of 22 participants who had no cognitive problems at the beginning of the study and who received the drug for an average of eight years. BGF investor Maggie Lau commented: 'The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer's drugs, sharpening the focus on early, accurate diagnosis. 'OBD's technology directly addresses this by enabling timely detection and precise monitoring of neurodegenerative disease.' "Oxford Brain Diagnostics initiates dementia diagnostic commercialisation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Oxford Brain Diagnostics initiates dementia diagnostic commercialisation
Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans. The UK company's cloud-based Cortical Disarray Measurement (CDM) Insights software processes MRI scan data to monitor patient brain changes across multiple stages of life, outputting the data as percentiles of a normative population distribution to provide an "objective, quantifiable measure of neurodegeneration". According to OBD, CDM's assessment of microstructural and macrostructural measurements, as well as cortical thickness, will bring methods of analysis to assist clinicians in the early detection of neurodegeneration currently unavailable on the US market. CDM Insights received a breakthrough device designation from the US Food and Drug Administration (FDA) in 2020 and 510(k) clearance from the agency in January 2025. Intended for use by healthcare practitioners, including neurologists and radiologists, OBD states that the CDM software will be made available to all US healthcare facilities. OBD CEO and co-founder Dr Steven Chance commented: 'Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage. 'These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease.' Spun out from the University of Oxford in 2018, OBD stated that it had reached this stage in its development due to a 2023 funding round led by the London-headquartered Business Growth Fund (BGF). This included additional support from existing investors, including the Oxford Technology & Innovations Fund (OTIF). Dr Chance continued: 'The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health.' The ability to detect neurodegenerative conditions earlier is an area of rising importance in pharmacology. A recent open-label extension (OLE) study (NCT06424236) of Roche's discontinued Alzheimer's drug, gantenerumab, showed signs that it could prevent the onset of the disease. Data from the OLE published in The Lancet demonstrated that the anti-amyloid drug cut the risk of developing symptoms by 50% for a subgroup of 22 participants who had no cognitive problems at the beginning of the study and who received the drug for an average of eight years. BGF investor Maggie Lau commented: 'The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer's drugs, sharpening the focus on early, accurate diagnosis. 'OBD's technology directly addresses this by enabling timely detection and precise monitoring of neurodegenerative disease.' "Oxford Brain Diagnostics initiates dementia diagnostic commercialisation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
NDTV
5 days ago
- Health
- NDTV
Revolutionary Brain Scan Detects Alzheimer's Before Symptoms Appear
Scientists have devised a world-first brain scanning technique that could identify signs of Alzheimer's disease, years before the symptoms appear. Using a technique called cortical disarray measurement (CDM) which analyses MRI scans to pinpoint more subtle signs of neurodegeneration, scientists are hoping to help millions with concerns about dementia. Currently, doctors diagnose diseases like dementia through a combination of questionnaires, which show memory problems and MRI scans. However, this process means people are diagnosed only when the disease has progressed. Through the new "precision diagnostic tool", doctors will be able to spot disruptions in the structure and function of the cortex, particularly those associated with functions such as memory, decision-making and language. "Our sophisticated diffusion analysis is based on a deep understanding of neuropathology, and the correlations between microscopic brain data and MRI analysis," British company Oxford Brain Diagnostics, which developed the novel technique, said in a statement. How does it work? As per the company, CDM is an all-in-one solution that is cloud native, non-invasive and monitors brain changes in patients across the multiple stages of adult life. CDM Insights processes clinical MRI scan data from both 1.5T and 3T scanners It then delivers outputs in the form of images and numerical values, usually presented as percentiles of a normative population distribution The proprietary technology has already been designated by the US Food and Drug Administration for use in the United States as a "breakthrough" device. Dr Steven Chance, former associate professor of neuroscience at Oxford, and Prof Mark Jenkinson, a leading expert in brain imaging, are the brains behind the company with UK investment firm BGF and the Oxford Technology & Innovations Fund providing the funding for the venture. Last month, researchers at Mass General Brigham also came up with an artificial intelligence (AI) tool capable of predicting brain decline in patients, years in advance. The AI tool analyses subtle changes in brain activity during sleep using electroencephalography (EEG) to make the prediction. During one of the studies, it correctly flagged 85 per cent of individuals who eventually experienced cognitive decline, with an overall accuracy of 77 per cent. According to the World Health Organization (WHO), about 55 million people worldwide live with dementia. Multiple studies have suggested that prior to the onset of cognitive impairment, alterations in behaviour and physiological functions may occur. Identifying these signals at the prodromal stages may potentially provide a better window for effective interventions.
The Age
6 days ago
- Health
- The Age
Brain scan to detect Alzheimer's before symptoms appear is world first
It has already been designated by the US Food and Drug Administration for use in the United States as a 'breakthrough' device. The neuroscientist behind the advances said it meant medical professionals were able to see changes in the brain far earlier, at a level normally only be possible via a post-mortem examination. Over the past year, two major treatments for Alzheimer's disease have been given the green light by UK regulators. Donanemab and lecanemab are the first treatments found to slow progression of the disease. Donanemab has just been approved for use in Australia, however is not yet available on the Pharmaceutical Benefits Scheme. Lecanemab has not received approval. Both have also been blocked for use on Britain's National Health Service, on the grounds they are not cost-effective. Experts believe that diagnosing dementia early is key to making treatments more effective and helping to ensure they become more widely available. Almost 1 million people in Britain are living with dementia, but this number is expected to reach 1.4 million by 2040. About 400,000 people have dementia in Australia. Oxford Brain Diagnostics, a spinout company from the University of Oxford, was founded by Dr Steven Chance, former associate professor of neuroscience at Oxford, and Professor Mark Jenkinson, a leading expert in brain imaging. Loading The breakthrough was achieved after the company received funding from British investment firm BGF and the Oxford Technology & Innovations Fund. Identify other neurodegenerative conditions Studies have found the method can detect neurodegenerative changes before any visible brain shrinkage or atrophy appears on standard imaging as well as distinguish between different types of dementia. It has also been found to predict which individuals with mild cognitive impairment are more likely to develop dementia. The platform could also help to identify other neurodegenerative conditions including Parkinson's disease and multiple sclerosis. Chance said: 'The core technology is founded on my background, looking at the microscopic structure of brains at autopsy for many years. You couldn't do that with a living patient and this is what we needed.' He said the technology could have a transformative impact, bringing hope to 'millions of people who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health'. For now, the target patient market is those suffering mild cognitive decline, allowing professionals to differentiate between types of dementia and other neurodegenerative diseases. Chance said clinics might offer annual checks for those with concerns about memory problems. In time, and with the advent of more medicines to treat dementia, such advances could be rolled out to those in mid-life, he said. 'More than 20 per cent of those over 50 have Alzheimer's-type changes, small-scale changes that would be otherwise invisible. These breakthroughs open up a whole new way of monitoring brain health.' Alzheimer's Research UK policy head David Thomas said: 'Dementia is caused by diseases that often begin years before symptoms appear, and so finding new ways to detect these diseases earlier is vital. There is a huge amount of progress happening in this space and it's encouraging to see UK companies contributing to that. 'While this technology shows promise for diagnosing dementia earlier, so far it has only been validated in research settings. We're still some way off it being used within the NHS and we would need to see much more real-world clinical data to fully understand its potential. Loading 'Improving early and accurate diagnosis is crucial – not only to give people clarity about their condition but also to ensure they can access the right support and, in future, new treatments as they become available.' The Telegraph, London
Sydney Morning Herald
6 days ago
- Health
- Sydney Morning Herald
Brain scan to detect Alzheimer's before symptoms appear is world first
It has already been designated by the US Food and Drug Administration for use in the United States as a 'breakthrough' device. The neuroscientist behind the advances said it meant medical professionals were able to see changes in the brain far earlier, at a level normally only be possible via a post-mortem examination. Over the past year, two major treatments for Alzheimer's disease have been given the green light by UK regulators. Donanemab and lecanemab are the first treatments found to slow progression of the disease. Donanemab has just been approved for use in Australia, however is not yet available on the Pharmaceutical Benefits Scheme. Lecanemab has not received approval. Both have also been blocked for use on Britain's National Health Service, on the grounds they are not cost-effective. Experts believe that diagnosing dementia early is key to making treatments more effective and helping to ensure they become more widely available. Almost 1 million people in Britain are living with dementia, but this number is expected to reach 1.4 million by 2040. About 400,000 people have dementia in Australia. Oxford Brain Diagnostics, a spinout company from the University of Oxford, was founded by Dr Steven Chance, former associate professor of neuroscience at Oxford, and Professor Mark Jenkinson, a leading expert in brain imaging. Loading The breakthrough was achieved after the company received funding from British investment firm BGF and the Oxford Technology & Innovations Fund. Identify other neurodegenerative conditions Studies have found the method can detect neurodegenerative changes before any visible brain shrinkage or atrophy appears on standard imaging as well as distinguish between different types of dementia. It has also been found to predict which individuals with mild cognitive impairment are more likely to develop dementia. The platform could also help to identify other neurodegenerative conditions including Parkinson's disease and multiple sclerosis. Chance said: 'The core technology is founded on my background, looking at the microscopic structure of brains at autopsy for many years. You couldn't do that with a living patient and this is what we needed.' He said the technology could have a transformative impact, bringing hope to 'millions of people who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health'. For now, the target patient market is those suffering mild cognitive decline, allowing professionals to differentiate between types of dementia and other neurodegenerative diseases. Chance said clinics might offer annual checks for those with concerns about memory problems. In time, and with the advent of more medicines to treat dementia, such advances could be rolled out to those in mid-life, he said. 'More than 20 per cent of those over 50 have Alzheimer's-type changes, small-scale changes that would be otherwise invisible. These breakthroughs open up a whole new way of monitoring brain health.' Alzheimer's Research UK policy head David Thomas said: 'Dementia is caused by diseases that often begin years before symptoms appear, and so finding new ways to detect these diseases earlier is vital. There is a huge amount of progress happening in this space and it's encouraging to see UK companies contributing to that. 'While this technology shows promise for diagnosing dementia earlier, so far it has only been validated in research settings. We're still some way off it being used within the NHS and we would need to see much more real-world clinical data to fully understand its potential. Loading 'Improving early and accurate diagnosis is crucial – not only to give people clarity about their condition but also to ensure they can access the right support and, in future, new treatments as they become available.' The Telegraph, London
